Lumos Secures 100% US Medicare Reimbursement for FebriDx
Filed with ASX · · 3 pages · English
Watch Lumos Diagnostics' latest callLumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call · Replay · Apr 20Read the transcript of Lumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call• Lumos has now secured 100% reimbursement recognition for FebriDx® from all Medicare Administration Contractors (MAC) at US$41.38 per test as listed in the CMS Clinical Lab Fee Schedule (CLFS). • National Government Services (NGS), seventh and final MAC to link FebriDx with the CLFS. Responsible for Illinois, Minnesota and Wisconsin, plus the New England and New York regions. • Focus now turns to
Lumos Diagnostics Holdings Ltd. on 6ix
Story so far
Earlier from Lumos Diagnostics
- Lumos secures follow-on PKU contract with Aptatek
- LDX & BARDA partner on new US$6.2m FebriDx Paediatric Study
- FY25 Appendix 4E
- Lumos Announces FebriDx CLIA Waiver Application Submission
- Lumos Signs Binding Term Sheet for A$5M Loan Facility
Later from Lumos Diagnostics
- Quarterly Activities/Appendix 4C Cash Flow Report
- Lumos Completes Enrolment Milestone for Paediatric Study
- Appendix 4D and Half Year Report
- Lumos Delivers Several Pivotal Milestones in 1H FY26
- Trading Halt
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics